Woodline Partners Adds $101M in DaVita Inc. ($DVA)

Key Points

  • Wall Street's consensus rating on $DVA is Buy and an average price target of $218.43.
  • $DVA last traded around $222.48.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Woodline Partners acquired a new position in DaVita Inc. ($DVA), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 452,979 shares of DaVita Inc.. Woodline Partners's holdings in DaVita Inc. were worth $100.78 million as of its most recent filing.

DaVita Inc. Stock Up 23.1%

Shares of DaVita Inc. ($DVA) traded around $222.48 on Saturday, up 23.1% for the day.

Last price$222.48
Market cap$11.23B
P/E ratio15.32
Forward P/E10.20
PEG ratio0.56
Beta0.87
52-week low$101
52-week high$247.49
50-day MA$210.80
200-day MA$162.90
Current ratio1.47
Quick ratio1.33
Debt-to-equity12.42

DaVita Inc. Earnings

EPS (ttm)$11.49
Revenue (ttm)$14.01B
Revenue growth5.20%
Net margin6.05%
Return on equity88.48%
Next earningsOct 28, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$218.43
High target$270
Low target$165
Analysts covering7

About DaVita Inc.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

ExchangeNYSE
SectorHealthcare
IndustryMedical Care Facilities
HeadquartersDenver, CO
CEOMr. Javier J. Rodriguez
Employees78,000

Get DaVita Inc. alerts

New 13F filings, insider trades, and analyst moves on $DVA, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.